pre-IPO PHARMA

COMPANY OVERVIEW

Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. Maze is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics and an array of drug discovery approaches. The Maze platform reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.mazetx.com


    CAREER WEBSITE

    https://mazetx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments arch-venture-partners casdin-capital foresite-capital gv third-rock-ventures


    PRESS RELEASES


    Sep 21, 2023

    Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference


    Jun 1, 2023

    Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference


    May 1, 2023

    Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease


    Mar 22, 2023

    Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease


    Feb 27, 2023

    Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease


    For More Press Releases


    Google Analytics Alternative